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HSV-1 infection in the cornea could lead to blindness. The infected cell polypeptide 4 (ICP4) of herpes simplex virus 1 (HSV-1)
is a regulator of viral transcription that is required for productive infection. It has been previously demonstrated that miR-H6
encoded from HSV-1 genome targets ICP4 to help maintain latency. In this study, synthesized miR-H6 mimics were transfected
into HSV-1-infected human cornea epithelial (HCE) cells. The inhibition of HSV-1 replication and viral ICP4 expression in miR-
H6-transfected HCE was conﬁrmed by plaque assay, immunoﬂuorescence, and Western blot. Compared to nontransfection or
mock,miR-H6producedalow-titerHSV-1andweakICP4expression.Inaddition,miR-H6candecreasetheinterleukin6released
intothemedium,whichwasdeterminedbyELISA.Takentogether,thedatasuggeststhatmiR-H6targetingofICP4inhibitsHSV-1
productive infection and decreases interleukin 6 production in HCE, and this may provide an approach to prevent HSV-1 lytic
infection and inhibit corneal inﬂammation.
1.Introduction
Herpes simplex virus type 1 (HSV-1) is a linear double-
stranded DNA virus that mainly infects epithelial and neu-
ronal cells. The productive infection of HSV-1 entails a cas-
cade of gene expression (immediate-early, early, and late
genes), viral DNA replication, assembly and egress of virus.
The immediate-early (IE) gene ICP4 (infected-cell polypep-
tide 4) of HSV-1 is one of the major regulatory genes requir-
ed for eﬃcient transcription of early and late viral genes
and drives HSV-1 through the productive replication cycle
[1, 2]. ICP4 also plays a role in reactivation of HSV-1 from
latency. The regulation of ICP4 seems to be exerted at the
posttranscriptionallevelbythelatency-associatedtranscripts
(LATs) [3, 4]. Inhibition of ICP4 gene can suppress viral pro-
duction in various cells [5–8].
MicroRNAs (miRNAs) are small, 21∼23 nucleotide non-
coding RNAs that play an important role in the post-trans-
criptional regulation of gene expression in a wide range of
organisms from unicellular eukaryotes to multicellular euka-
ryotes by a variety of mechanisms [9]. The existence of viral
miRNAswasﬁrstreportedinEpstein-Barrvirusin2004[10].
The discovery of miRNAs encoded by viruses suggests that
viruses have evolved to exploit RNA silencing for regulation
of their own genes, host genes, or both and contribute to the
functions including (I) latent and lytic viral infection, (II)
immune evasion, (III) prevention of apoptosis, (IV) viral
replication, and (V) others [11–13]. As for HSV-1, the ﬁrst
microRNA, miR-H1, expressed as a late gene in productive
infection, was reported in 2006 [14]. Also, HSV-1 infection
of human brain cells inducing a miRNA-146a that mediates
inﬂammatory signaling was ﬁrstly reported in 2009 [15]. Up
to now, 16 HSV-1 miRNAs have been found [4, 12, 14, 16].
Of them, both miR-H1 and miR-H6 are located upstream
to the LAT promoter. miR-H1 is encoded by sequences
upstream of the LAT promoter in the LAT sense direction,
while miR-H6 is located in an LAT antisense direction [16].
Umbach et al. ﬁrst found that miR-H6 downregulates the
expression of ICP4 proteins, suggesting a contribution to the
establishment and maintenance of viral latency [4]. Simi-
larly, the latent infection is characterized by the abundantly
expressed locus that encodes the LAT, which can repress
lytic replication and IE gene expression in a neuronal cell
line [3]. However, miR-H6 and H1, detected as early as2 Clinical and Developmental Immunology
2hr postinfection (p.i.) in cultured cells, were abundantly
expressedintheHSV-1productiveinfectionsample,whereas
the other HSV-1 miRNAs (i.e., miR-H2, -H3, and -H4) were
greatly produced during the latent infection [16, 17]. Mean-
while, miR-H6 expression was signiﬁcantly reduced in cells
infected with a mutant HSV-2 virus with an insertion of a
sequence between the LAT promoter and miR-H6 [18], and
also in latently, but not in acutely, infected mouse ganglia
with HSV-1 LAT deletion mutants (dlLAT1.8) [17]. These
results suggested that when miR-H6 is expressed abundantly
during lytic infection, it may play other roles during viral
infection besides establishing and maintaining the latent
infection [12, 17].
As a major pathogen to human beings, HSV-1 can cause
a variety of diseases and can even be life threatening [19, 20].
Common ocular manifestations of HSV-1 infection include
blepharitis, conjunctivitis, keratitis, and uveitis; of them, re-
currentviralkeratitiscanleadtoseverecornealblindness[2].
In addition, the cornea tissue was suggested to be the site
where HSV-1 can establish latent infection [2, 21, 22]. The
corneal epithelium is composed of several layers of cells in
front of the stroma. Thus, it is given the important role of
protecting from the invasion of exogenous viruses. The pri-
maryinfectionofHSV-1incornealepithelialcellsistypically
displayed by dendritic lesions. However, HSV-1induced ker-
atitis also frequently appeared, as the immunopathology of
inﬂammation was not directly produced by a great number
of lytic infection of virus [23–26]. In such cases, cytokines
playimportantrolesinthevirus-inducedimmunopathology.
One cytokine known to contribute to immune response
to HSV-1 is interleukin-6 (IL-6), which is a cytokine with
pleiotropic activities, including both proinﬂammatory and
anti-inﬂammatory activities [27]. Meanwhile, within the
LAT and ICP0 promoter of HSV-1, there are IL-6 response
elements, possible binding sites of the IL-6-induced trans-
cription factors. Viral constructs with deletion of the IL-6
response element in the LAT promoter reactivate at much
lower rates than similar constructs without the deletion
[28]. IL-6 induced by HSV-1 infection has been reported
in various cells such as leukocytes [29], epithelial cell EMT-
6, and HaCat [30, 31], as well as cornea epithelial cells and
ﬁbroblasts [32].
Regarding the abundant expression in lytic infection and
thelocationofmiR-H6encodingsequence(upstreamofLAT
promoter), we wonder whether miR-H6 has diﬀerent func-
tions compared to other miRNAs (miR-H2-miR-H5) in
HSV-1 infection. We therefore investigated the eﬀects of
miR-H6 targeting of ICP4 on HSV-1 replication, in particu-
lar, the eﬀects on IL-6 production in human cornea cells. We
found that miR-H6 targeting of ICP4 suppresses HSV-1 rep-
lication and decreases IL-6 production in HCE, and this may
provide an approach to prevent HSV-1 lytic infection and
inhibit inﬂammation in cornea.
2.MaterialsandMethods
2.1. Cells and Virus Infection. HCE used in this study was
derived from human limbal cells as described previously
[33, 34]. Cells were cultured in DMEM/high-glucose supple-
mentedwith10%fetalbovineserum(FBS;Gibco,NY,USA),
10ng/mL human epidermal growth factor (EGF; Sigma, St.
Louis, MO), 5μg/mL human transferrin (Sigma), 5μg/mL
insulin, and 0.4μg/mL hydrocortisone (Gibco BRL, Grand
Island, NY). HEp-2 cells were grown in DMEM/F12 with
10% newborn bovine serum (Gibco, NY, USA). The cells
were incubated at 37◦Ci na5 %C O 2-95% air incubator.
Stocks of the HSV-1 (F strain) were propagated on HEp-2
cells, and the titer of virus stocks was determined according
to a previously described method [35].
HCE cells were infected by HSV-1 using a previously
described method [5, 34]. Brieﬂy, cells were cultured to 80
to 90% conﬂuence, then infected with HSV-1 for 1h, with
gentle 15sec shaking every 15min to allow viral absorption.
After 1h, the inoculum was removed and the medium
was replaced with serum-free DMED/high-glucose. Cells
infected at a multiplicity of infection (MOI) of 5, 1, 0.1, were
washed with phosphate-buﬀered saline (PBS) three times
and harvested.
2.2. HSV-1 miR-H6 Mimics and Transfection. The miR-H6
mimics we used were double-stranded, chemically synthe-
sized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China)
according to the mature miR-H6 (5 -CACUUCCCGUCC-
UUCCAUCCC-3 ). The mock is a small RNA that does not
target any known gene as a negative control. The HCE cells
were grown to 70–80% conﬂuence and then transfected with
miR-H6 (50 or 100nM) and mock, by Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA), according to the manu-
facturer’s instructions. Then, the cells are infected with HSV-
1 at MOI 0.1 24h posttransfection. At the indicated time, the
cells and medium were harvested for further experiments.
2.3. Plaque Assays. The plaque assay was performed as we
described previously, but with modiﬁcation [5]. HCE cells
were grown in 12-well plates to 70 to 80% conﬂuence and
then transfected with miR-H6 mimics and infected with
HSV-1asdescribedabove.AfterabsorbingtheHSV-1for1h,
cells were overlaid with 1mL of a 1:1 mixture of low-melt-
ing-temperature agarose (NuSieve GTG Agarose, USA) and
2 × DMEM/high glucose to permit only cell-to-cell spread
of virus. At 48h p.i., agarose was removed carefully and
plates were stained with crystal violet for 20min and then
photographed. Finally, plaque sizes were measured.
2.4. Real-Time PCR Analysis. HCE cells were cultured to 80
to 90% conﬂuence and then infected with HSV-1 in a multi-
plicity of infection (MOI) of 5, 1, and 0.1. At 24h p.i., cells
were washed with PBS three times and harvested. Cellular
total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad,CA,USA)accordingtothemanufacturer’sinstruc-
tions. Subsequently, RNA samples were detected using an
All-in-One miRNA Q-PCR Detection kit (FulenGen, Guan-
gzhou, China). The miR-H6 5  primers were CACTTC-
CCGTCCTTCCATCCCA (product size is 74) and homo
snRNA U6 5  primers were CAAATTCGTGAAGCGTTC-
CATAT (product size is 79). The reaction conditions wereClinical and Developmental Immunology 3
95◦C for 10min, 38 cycles of 95◦C for 10s, 65◦Cf o r2 0s ,
and 72◦C for 10s and 72◦C for 5min by iQ5 Real-Time PCR
DetectionSystem(Bio-Rad).TheamountofeachmRNAwas
calculated relative to the amount of U6 mRNA in the same
samplesbyiQsoftware.Eachrunwascompletedwithamelt-
ing curve analysis to conﬁrm the speciﬁcity of the ampliﬁca-
tion.
2.5. Indirect Immunoﬂuorescence. At 12 and 24h p.i., slide-
mounted cells were used for indirect immunoﬂuorescence
analysis according to the method described previously [5].
Cells were incubated with mouse anti-human monoclonal
antibody that recognizes HSV-1 ICP4 (Abcam, Cambridge,
UK) at 4◦C overnight. Cells were then incubated with
TRITC-conjugated secondary goat anti-mouse IgG antibody
(Zhongshan Goldenbridge, Beijing, China) at 37◦Cf o r1h .
The nuclei were stained with hoechst for 10min. Cells were
then observed using a confocal laser scanning microscope
(Carl Zeiss, Jena, Germany). Cells incubated with PBS
(instead of the ﬁrst antibody) were used as negative controls.
2.6. Western Blot Analysis. At 24h p.i., cells were lysed with
lysate buﬀer (20nM tris-HCL). The samples were freeze-
thawed 3 times and then centrifuged at 12,000rpm for
30min at 4◦C to remove cellular debris. Protein content in
the supernatant was determined by the bicinchoninic acid
method using BSA as the standard. Western blot was con-
ducted according to our previous method [5]. The mem-
branes were incubated with 1μg/mL of mouse anti-human
monoclonal antibodies that recognizes HSV-1 ICP4 (Abcam,
Cambridge, UK) or 0.2μg/mL mouse anti-GAPDH (Kang-
Chen, Shanghai, China) separately at 4◦C overnight. Then,
they were exposed to a secondary goat anti-mouse IgG
antibody (Zhongshan Goldenbridge, Beijing, China) for 1h.
Protein bands were visualized with a kit of chemiluminesce-
ncePhototope(R)-HRPWesternBlotDetectionSystem(Cell
Signaling Technology, Inc., Danvers, MA, USA) and exposed
by Kodak Imaging Station 4000MM (Kodak, Rochester, NY,
USA).
2.7. Enzyme-Liked Immunosorbent Assay (ELISA). The HCE
cells were transfected with miR-H6 and mock and then
infected with HSV-1 as described above, or directly cultured
the transfected cells without virus infection. The medium
was collected at 6, 12, and 24h p.i., or 30, 36, and 48h post
transfection for cells without HSV-1 infection, and the IL-6
levels in supernatant were determined using a speciﬁc IL-6
ELISA kit (Boster, Wuhan, China). Human IL-6 was used to
construct a standard curve according to the manufacturer’s
instructions.
2.8. Statistical Analysis. All experiments were repetitively
conducted a minimum of three times, and the quantitative
data was expressed as means ± SD. Statistical analysis of
data was performed by one-way ANOVA (SPSS 17.0), with
P<0.05 considered statistically signiﬁcant.
3. Results
3.1. miR-H6 Eﬀects on Cells and Viral Replication. HCE cells
were transfected and infected HSV-1 at MOI 0.1 as described
above, and cellular morphological changes were observed
at 6, 12, and 24h p.i. under phase-contrast microscopy
(Figure 1(a)). At 6h p.i., there were no obvious diﬀere-
nces in cellular morphology among cells transfected with
miR-H6, the mock, without small RNA, and control cells
(data not shown). At 12h p.i., the cytopathic eﬀect (CPE)
could be observed in the mock and without small RNA
cells, but not in the cells transfected with miR-H6 and con-
trol. Infected cells usually displayed clusters, and many indi-
vidual cells remained uninfected. At 24h p.i., CPE increased
dramatically, and many giant, multinucleated cells could be
seen in the mock and without small RNA cells. However,
fewer CPE could be seen in cells transfected with miR-H6,
including multinucleated giant cells.
PlaqueassaywasusedtodetectthevirusquantityinMOI
0.1HSV-1-infectedHCEcellsanddemonstratedthatnormal
cell had no formation of plaque, and HSV-1 without small
RNAresultedintheformationofalargernumberofplaques,
which was similar to the mock. However, treatment with
miR-H6signiﬁcantlydecreasedtheplaquesizesandnumbers
(Figure 1(b)) and had signiﬁcant diﬀerence (Figure 1(c),
P<0.05). Meanwhile, miR-H6 was measured in HSV-
1-infected HCE with MOI 5, 1, and 0.1, at 24h p.i. The
result showed that miR-H6 increased signiﬁcantly in HSV-1-
infected HCEs, and the expression of miR-H6 was consistent
with the concentration of the infectious virus quantity
(Figure 1(d), P<0.01). The uninfected HCE cells had no
expression of miR-H6.
3.2. miR-H6 Suppresses ICP4 Protein Expression. First, the
ICP4protein expression wasobserved by indirect immunoﬂ-
uorescence at 12 and 24h p.i. Following HSV-1 infection
and up to 12h p.i., there was very weak ICP4 staining in
HCE cells transfected with mock, and without mall RNA,
less ICP4 expression was noted in HCE cells transfected with
miR-H6; ICP4 was not observed in normal HCE control
cells (Figure 2(a)). At 24h p.i., the ICP4 protein expression
increased dramatically. Compared with the cells transfected
with mock and cells without small RNA, the intensity of
immunostaining for ICP4 was dramatically weaker in the
HCE cells transfected with miR-H6 (Figure 2(b)).
The eﬀect of miR-H6 on the ICP4 protein was also
detected by Western blot using antibodies against ICP4
(Figure 2(c)). At 24h p.i., the expression of ICP4 decreased
in the lysate of HCE cells transfected with miR-H6, whereas
the expression in small RNA untreated cells and in mock
remained constant (Figure 2(d), P<0.05). Similarly, there
was no expression of ICP4 in normal HCE cells.
3.3. The Eﬀe c to fm i R - H 6o nI L - 6R e l e a s e .The IL-6 pro-
tein expression in the medium was determined by ELISA
(Figure 3). At 6h p.i., the IL-6 level in medium of HCE cells
transfected with miR-H6 was lower than that with mock
and without small RNA; however, there was no signiﬁcant4 Clinical and Developmental Immunology






















































































Figure 1: miR-H6 eﬀects on cell changes and viral replication in HSV-1-infected HCE cells. HCE cells were transfected miR-H6 mimics and
mock, followed by infection with MOI 0.1 of HSV-1 24h posttransfection. (a) The cellular morphological changes were imaged at 12h and
24h postinfection. CPE clearly increased, and many multinucleated giant cells could be seen in the cells treated with mock RNA and cells
untreated with small RNA; fewer CPE and giant multinucleated cells could be seen in cells transfected with miR-H6 mimics. (b, c) Plaque
assay showed that treatment with miR-H6 decreased the plaque sizes and numbers and had a statistically signiﬁcant diﬀerence (P<0.05).
Cells were treated with miR-H6 mimics (0, 50, 100nM) and mock RNA (mock) or without small RNA (HSV-1). The control group (Ctl)
consisted of cells without virus infection and small RNA treatment. (d) Real-time PCR determined miR-H6 expression in pooled HSV-1-
infected HCE cells, and miR-H6 levels were changed in a viral-titer-dependent manner (
∗P<0.01, one-way ANOVA, among MOI 0.1, 1,
and 5).
diﬀerence (P>0.05). At 12h p.i., the IL-6 level in HCE
cells transfected with miR-H6 was dramatically lower than
in those transfected with mock or without small RNA
(Figure 3(a), P<0.01). At 24h p.i., the IL-6 levels in HCE
transfected with mock and without small RNA decreased as
compared to those at 12h p.i. The IL-6 level in medium of
cells transfected with miR-H6 is insigniﬁcantly lower when
compared to the level of mock transfection or that of only
HSV-1-infected cells. The latter two showed signiﬁcantly
higher levels as compared to the control (P<0.05).
The eﬀects of miR-H6 on IL-6 production of HCE cells
were assayed by comparison of the IL-6 levels in HCE
cells transfected with miR-H6 and mock and normal cells
(Figure 3(b), P>0.05). IL-6 did not alter signiﬁcantly
among all the groups at various time points.
4. Discussion
During HSV-1 lytic infection, ICP4 upregulates the early
and late genes, downregulates the IE genes through inter-
action with the transcription factors associated with RNA
polymerase II, and represses the LAT promoter and prevents









































Figure 2: miR-H6 decreased ICP4 protein expression in HSV-1-infected HCE cells. HCE cells were transfected with miR-H6 mimics and
mock RNA and then infected with MOI 0.1 of HSV-1 24h posttransfection. The staining of ICP4 protein in HCE cells at 12h p.i. (a) and
at 24h p.i. (b) TRITC labeled the antibody-stained ICP4 (red, left) and the hoechst-dyed nucleus (blue, middle). Images of ICP4 and the
nucleus were merged (right), scalebar: 20μm. (c) The ICP4 band was determined by Western blot. (d) Quantitative analysis of bands in (c).
Signiﬁcantly lower levels of ICP4 in HCE cells transfected with miR-H6 (
∗P<0.0 5 ,m i R - H 6v e r s u sm o c ko rH S V - 1a l o n e ) .
miR-H6 [4]. Therefore, we began this study with the goal
of observing the eﬀect of miR-H6 on HSV-1 replication
and the inﬂammatory cytokine IL-6 production in HCE, by
whichHSV-1infectionscanleadtocorneablindness[21,38].
We found that miR-H6 suppressed the expression of ICP4
protein and inhibited the HSV-1 productive infection in
HCE and in human retinal pigment epithelial cells (data not
shown). A similar result was reported by Umbach et al., who
found that miR-H6 inhibits expression of ICP4 in 293T cells
cotransfected with a synthetic miR-H6 duplex intermediate
and with plasmids expressing either wild-type ICP4 or the
ICP4 mutant [4]. Because viral miRNA regulation is depen-
dent on the context of infection, such as cell-type and viral
genome expression, we focused on the HSV-1-infected HCE
to investigate miR-H6 roles on the productive infection.
The highly abundant expressions of microRNAs in
HSV-1latentinfectionwerefoundinpreviousstudies,which
led to the concept that microRNA plays important roles in
establishing and/or maintaining latent infections [4, 16, 39].
However, by experiments in acute and latent ganglionic
infection in mice and lytic infection in Vero cells infected
with wide-type or LAT deletion mutant HSV-1, Kramer et al.
found that LAT deletion mutants establish and maintain
latent infections and concluded that microRNAs are not
essential for latency in mouse trigeminal ganglia, but may
help promote it [17]. Du and colleagues found that the
expression of viral genes in explanted ganglia was disordered
ratherthansequentiallyorderedasininfectedcellsinculture,
and the accumulation of viral mRNAs takes place concur-






















































































Figure 3: The eﬀect of miR-H6 on IL-6 release in medium. HCE cells were transfected with miR-H6 and infected with MOI 0.1 of HSV-
1 after 24h posttransfection (a) or without viral infection (b). The IL-6 level in medium was measured at indicated time p.i. by ELISA.
∗Statistical diﬀerence between HCE cells transfected with miR-H6 mimics and mock or HSV-1 alone (P<0.01); +/++statistical diﬀerence
between normal HCE cells and mock or HSV-1 alone (
+P<0.05;
++P<0.01).
which was degraded by a viral gene product other than
the short half-life of these miRNAs/LATs [40]. Nevertheless,
studies on quantities of HSV-1 mircroRNAs revealed that
miR-H6 and miR-H1 in the productive infection were the
most abundant, whereas miR-H2, -H3, and -H4 were greatly
expressed in the latent samples [4, 16, 17]. We also revealed
that the expression of miR-H6 in HSV-1-infected HCE cells
increases with viral concentration. All these data suggest
that HSV-1 microRNAs may have stage-speciﬁc functions
in the virus life cycle and that highly abundant levels of
miR-H6 may have other roles in lytic infection other than
maintaining the latent infection [17]. In our present study,
we are interested in miR-H6 silencing ICP4 by transfecting
synthesized miR-H6 mimics into HCE cells and followed
by HSV-1 infection. More studies on miR-H6, such as
interference with its function, and precise analysis of time-
dependenteﬀectsinlyticinfectionwouldhaveagreatereﬀect
on our understanding of the virus and its induced diseases.
HSV-1 infection in cornea is characterized by recurrent
viral lytic infection, immune inﬂammation, neovasculari-
sation, and so on. IL-6, as an important cytokine, targets
multiple cell types and induces a broad array of responses.
These responses are often, simplistically, classiﬁed as pro-or
anti-inﬂammatory in nature [41]. It was showed that two
majorsignaltransductionpathwaysregulatedbyIL-6:STAT3
and SHP2/Gab/MAPK signaling, which involve the gp130
YxxQ and Y759 motives, respectively [42]. IL-6 plays impor-
tant roles in these corneal pathological changes, which has
been evidenced by previous studies [38, 43–46]. Also, HSV-1
infection inﬂuencing IL-6 has been previously reported.
By using HSV-1 mutants lacking the virion-transactivating
protein VP16 or any of ICP0, ICP4, ICP8, or ICP27, virus-
infected leukocytes or murine epithelial cell line EMT-6
displayed unaltered capacities to induce IL-6 [29, 30]. Thus
any one of them alone is not essential for IL-6 production.
It was reported recently that in Kaposi’s sarcoma-associated-
herpes-virus-(KSHV-) infected cells, miR-1293, targeting
viral IL-6 RNA, and miR-608, targeting human IL-6 ORF,
can mechanistically compete with KSHV ORF57 protein,
which binds RNA export factor (REF) at the same site and
in a similar way to ICP27, and thus inﬂuence IL-6 produc-
tion [47, 48]. Although in the present study we did not
know if there was a target sequence of miR-H6 in HCE, we
did not ﬁnd miR-H6 suppressing IL-6 release in HCE with-
out HSV-1 infection. Therefore, the miR-H6 decreasing
IL-6 production in HSV-1-infected HCE cells is due to the




1 productive infection in HCE cells as well as accompanied
IL-6release.SilencingviralmicroRNAtargetsasanovelanti-
viral therapy, our result may imply that in diseased tissue like
keratitis, using miR-H6 could not only suppress viral repli-
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